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Table 1 Baseline characteristics of patients before and after propensity score matching 
  Before propensity score matching   After propensity score matching 
  Untreated Treated 
Standardized 
difference   Untreated Treated 
Standardized 
difference 




Age, mean±sd 81.1±9.4 79.4±8.5 0.186 
 
79.4 ±10.0 79.4±8.5 0.004 
Female, n (%) 22043 (69.2)   3087 (79.2)  0.229 
 
 6150 (78.8)   3087 (79.2)  0.008 
Medical history, n (%) 
       
Cogestive heart failure  3191 (10.0)    288 ( 7.4)  0.094 
 
  610 ( 7.8)    288 ( 7.4)  0.016 
Stroke  4380 (13.8)    422 (10.8)  0.089 
 
  839 (10.8)    422 (10.8)  0.002 
Ischaemic heart disease  3748 (11.8)    373 ( 9.6)  0.071 
 
  786 (10.1)    373 ( 9.6)  0.017 
Atrial fibrillation  2631 ( 8.3)    263 ( 6.7)  0.058 
 
  541 ( 6.9)    263 ( 6.7)  0.008 
Embolism    47 ( 0.1)      3 ( 0.1)  0.021 
 
    7 ( 0.1)      3 ( 0.1)  0.004 
Chronic Obstructive Pulmonary Disease  2969 ( 9.3)    341 ( 8.7)  0.02 
 
  699 ( 9.0)    341 ( 8.7)  0.008 
Diabetes mellitus  6542 (20.5)    872 (22.4)  0.044 
 
 1710 (21.9)    872 (22.4)  0.01 
Liver disease   235 ( 0.7)     20 ( 0.5)  0.029 
 
   39 ( 0.5)     20 ( 0.5)  0.002 
Chronic kidney disases  1555 ( 4.9)    101 ( 2.6)  0.121 
 
  180 ( 2.3)    101 ( 2.6)  0.018 
Rheumatic/collagen disorders   183 ( 0.6)     67 ( 1.7)  0.108 
 
  115 ( 1.5)     67 ( 1.7)  0.019 
Dementia  2688 ( 8.4)    133 ( 3.4)  0.214 
 
  230 ( 2.9)    133 ( 3.4)  0.026 
Osteoporosis  1393 ( 4.4)    413 (10.6)  0.238 
 
  786 (10.1)    413 (10.6)  0.017 
Other fractures  3145 ( 9.9)    458 (11.7)  0.06 
 
  954 (12.2)    458 (11.7)  0.015 
Paget's disease of bone     9 ( 0.0)      0 ( 0.0)  0.024 
 
    0 ( 0.0)      0 ( 0.0)  - 




Table 2 Crude risk estimate of mortality in patients treated with anti-osteoporosis medications before propensity score matching 
A) All-cause mortality 
Group N 




per 100 py 
Relative risk 
 (95% CI) 




per 100 py 
Relative risk 
 (95% CI) 
P 
Untreated 31846 4036/29596 13.6  - - 
 
17977/135043 13.3  - - 
Treated 3900 217/3788 5.7 0.42 (0.37-0.48) <0.001 
 
1478/18599 7.9 0.6 (0.56-0.63) <0.001 
Stratified by individual drug 
     
    
Alendronate 2739 126/2608 4.8 0.35 (0.3-0.42) <0.001 
 
901/11852 7.6 0.57 (0.53-0.61) <0.001 
Ibandronate 541 26/479 5.4 0.4 (0.27-0.58) <0.001 
 
203/2532 8 0.6 (0.52-0.68) <0.001 
Risedronate 108 5/95 5.3 0.38 (0.16-0.92) 0.032 
 
34/518 6.6 0.49 (0.35-0.68) <0.001 
Zoledronate 141 9/130 6.9 0.51 (0.26-0.97) 0.042 
 
29/447 6.5 0.5 (0.34-0.71) <0.001 
Denosumab 30 1/28 3.6 0.26 (0.04-1.86) 0.18 
 
6/79 7.6 0.59 (0.26-1.31) 0.193 
Raloxifene 7 2/6 33.3 2.31 (0.58-9.23) 0.237 
 
3/28 10.7 0.8 (0.26-2.47) 0.692 
HRT 1 0/1 0 - - 
 
0/10 0 - - 
Salcatonin 166 27/124 21.8 1.58 (1.08-2.31) 0.018 
 
84/513 16.4 1.23 (0.99-1.52) 0.061 
Strontium ranelate 140 13/121 10.7 0.78 (0.45-1.35) 0.379 
 
61/517 11.8 0.88 (0.69-1.14) 0.338 
Teriparatide 27 0/23 0 - - 
 
2/59 3.4 0.26 (0.07-1.04) 0.058 
Stratified by drug class 
     
    
Bisphosphonate 3529 166/3312 5 0.37 (0.32-0.43) <0.001 
 
1167/15349 7.6 0.57 (0.54-0.61) <0.001 
Non-bisphosphonate 371 43/304 14.1 1.03 (0.77-1.4) 0.831 
 
156/1205 12.9 0.97 (0.83-1.14) 0.732 
PS trimming^ 3705 203/3602 5.6 0.4 (0.35-0.46) <0.001  1338/17463 7.7 0.56 (0.53-0.59) <0.001 
Abbreviations: py person-year; HRT hormone replacement therapy; PS propensity score 
^excluded treated patients with PS below 5% of that in treated group or untreated patients with PS above 95% of that in untreated group. 
  









per 100 py 
Relative risk 
 (95% CI) 




per 100 py 
Relative risk 
 (95% CI) 
P 
Untreated 28545 735/28085 2.6  - - 
 
16528 2659/86556 3.1  - - 
Treated 3739 56/3709 1.5 0.58 (0.44-0.76) <0.001 
 
2671 249/14265 1.7 0.56 (0.49-0.63) <0.001 
Stratified by individual drug 
     
     
Alendronate 2645 32/2558 1.3 0.48 (0.34-0.68) <0.001 
 
2002 164/9391 1.7 0.54 (0.46-0.64) <0.001 
Ibandronate 522 7/469 1.5 0.57 (0.27-1.2) 0.136 
 
370 32/1864 1.7 0.56 (0.4-0.8) 0.001 
Risedronate 104 1/93 1.1 0.41 (0.06-2.91) 0.371 
 
78 4/401 1 0.34 (0.13-0.9) 0.03 
Zoledronate 132 0/127 0  - -  - 114 2/393 0.5 0.15 (0.04-0.59) 0.007 
Denosumab 30 1/28 3.6 1.36 (0.19-9.65) 0.76 
 
26 2/71 2.8 0.77 (0.19-3.07) 0.708 
Raloxifene 5 0/5 0  - - 
 
4 0/21 0  - - 
HRT 1 0/1 0  - - 
 
1 0/10 0  - - 
Salcatonin 148 9/119 7.6 2.85 (1.48-5.51) 0.002 
 
95 13/275 4.7 1.46 (0.85-2.52) 0.173 
Strontium ranelate 132 5/118 4.2 1.61 (0.67-3.88) 0.289 
 
94 15/379 4 1.24 (0.74-2.05) 0.415 
Teriparatide 27 0/23 0  - - 
 
25 0/50 0  - - 
Stratified by drug class 
     
     
Bisphosphonate 3403 40/3246 1.2 0.47 (0.34-0.65) <0.001 
 
2564 202/12049 1.7 0.53 (0.46-0.61) <0.001 
Non-bisphosphonate 343 15/294 5.1 1.93 (1.16-3.23) 0.011 
 
245 30/806 3.7 1.14 (0.79-1.63) 0.487 
PS trimming^ 3555 53/3526 1.5 0.56 (0.43-0.74) <0.001  2589 222/13628 1.6 0.49 (0.43-0.56) <0.001 
Abbreviations: py person-year; HRT hormone replacement therapy; PS propensity score 
^excluded treated patients with PS below 5% of that in treated group or untreated patients with PS above 95% of that in untreated group. 
  
Table 3 Risk estimate of mortality in patients treated with anti-osteoporosis medications after propensity score matching 
A) All-cause mortality 
Group N 




per 100 py 
Relative risk 
 (95% CI) 




per 100 py 
Relative risk 
 (95% CI) 
P 
Untreated 7800 810/7334 11  - - 
 
3442/32132 10.7  - - 
Treated 3900 217/3788 5.7 0.52 (0.45-0.6) <0.001 
 
1478/18599 7.9 0.74 (0.69-0.78) <0.001 
Stratified by individual drug 
     
    
Alendronate 2739 126/2608 4.8 0.44 (0.36-0.53) <0.001 
 
901/11852 7.6 0.71 (0.66-0.76) <0.001 
Ibandronate 541 26/479 5.4 0.49 (0.33-0.73) <0.001 
 
203/2532 8 0.73 (0.64-0.85) <0.001 
Risedronate 108 5/95 5.3 0.47 (0.2-1.14) 0.095 
 
34/518 6.6 0.6 (0.43-0.84) 0.003 
Zoledronate 141 9/130 6.9 0.63 (0.32-1.21) 0.161 
 
29/447 6.5 0.62 (0.43-0.9) 0.012 
Denosumab 30 1/28 3.6 0.32 (0.05-2.3) 0.259 
 
6/79 7.6 0.75 (0.34-1.67) 0.481 
Raloxifene 7 2/6 33.3 2.85 (0.71-11.4) 0.14 
 
3/28 10.7 0.98 (0.32-3.05) 0.978 
HRT 1 0/1 0  - - 
 
0/10 0  - - 
Salcatonin 166 27/124 21.8 1.95 (1.33-2.87) <0.001 
 
84/513 16.4 1.52 (1.23-1.89) <0.001 
Strontium ranelate 140 13/121 10.7 0.97 (0.56-1.67) 0.903 
 
61/517 11.8 1.1 (0.85-1.42) 0.458 
Teriparatide 27 0/23 0  - - 
 
2/59 3.4 0.33 (0.08-1.33) 0.12 
Stratified by drug class 
     
    
Bisphosphonate 3529 166/3312 5 0.45 (0.38-0.54) <0.001 
 
1167/15349 7.6 0.71 (0.66-0.76) <0.001 
Non-bisphosphonate 371 43/304 14.1 1.28 (0.94-1.73) 0.12 
 
156/1205 12.9 1.21 (1.03-1.42) 0.019 
PS trimming^ 3705 203/3602 5.6 0.53 (0.46-0.62) <0.001  1338/17463 7.7 0.72 (0.67-0.77) <0.001 
Abbreviations: py person-year; HRT hormone replacement therapy; PS propensity score 
^excluded treated patients with PS below 5% of that in treated group or untreated patients with PS above 95% of that in untreated group. 
  









per 100 py 
Relative risk 
 (95% CI) 




per 100 py 
Relative risk 
 (95% CI) 
P 
Untreated 7149 159/7041 2.3  - - 
 
4884 526/23750 2.2  - - 
Treated 3739 56/3709 1.5 0.67 (0.49-0.91) 0.01 
 
2671 249/14265 1.7 0.8 (0.69-0.93) 0.003 
Stratified by individual drug 
     
     
Alendronate 2645 32/2558 1.3 0.55 (0.38-0.81) 0.002 
 
2002 164/9391 1.7 0.78 (0.66-0.93) 0.007 
Ibandronate 522 7/469 1.5 0.66 (0.31-1.41) 0.28 
 
370 32/1864 1.7 0.8 (0.56-1.15) 0.227 
Risedronate 104 1/93 1.1 0.47 (0.07-3.39) 0.458 
 
78 4/401 1 0.47 (0.18-1.27) 0.137 
Zoledronate 132 0/127 0  - - 
 
114 2/393 0.5 0.21 (0.05-0.86) 0.03 
Denosumab 30 1/28 3.6 1.58 (0.22-11.25) 0.651 
 
26 2/71 2.8 1.14 (0.28-4.57) 0.855 
Raloxifene 5 0/5 0  - - 
 
4 0/21 0  - - 
HRT 1 0/1 0  - - 
 
1 0/10 0  - - 
Salcatonin 148 9/119 7.6 3.32 (1.7-6.5) <0.001 
 
95 13/275 4.7 2.09 (1.2-3.62) 0.009 
Strontium ranelate 132 5/118 4.2 1.87 (0.77-4.55) 0.168 
 
94 15/379 4 1.78 (1.07-2.98) 0.027 
Teriparatide 27 0/23 0  - - 
 
25 0/50 0  - - 
Stratified by drug class 
     
     
Bisphosphonate 3403 40/3246 1.2 0.55 (0.39-0.77) <0.001 
 
2564 202/12049 1.7 0.76 (0.64-0.89) <0.001 
Non-bisphosphonate 343 15/294 5.1 2.25 (1.32-3.82) 0.003 
 
245 30/806 3.7 1.64 (1.14-2.37) 0.008 
PS trimming^ 3555 53/3526 1.5 0.69 (0.51-0.95) 0.022  2589 222/13628 1.6 0.76 (0.65-0.89) <0.001 
Abbreviations: py person-year; HRT hormone replacement therapy; PS propensity score 
^excluded treated patients with PS below 5% of that in treated group or untreated patients with PS above 95% of that in untreated group. 
  
Table 4 Risk estimate of CVD mortality in patients after propensity score matching, stratified by baseline CVD 









per 100 py 
Relative risk 
 (95% CI) 




per 100 py 
Relative risk 
 (95% CI) 
P 
Untreated 5419 77/5362 1.4  - - 
 
3715 285/18379 1.6  - - 
Treated 2808 31/2790 1.1 0.77 (0.51-1.17) 0.229 
 
2071 136/11361 1.2 0.78 (0.64-0.96) 0.019 
Stratified by individual drug 
     
     
Alendronate 2016 18/1951 0.9 0.64 (0.38-1.07) 0.091 
 
1559 88/7504 1.2 0.76 (0.6-0.96) 0.022 
Ibandronate 378 3/336 0.9 0.62 (0.2-1.96) 0.414 
 
284 15/1487 1 0.68 (0.4-1.14) 0.14 
Risedronate 85 1/74 1.4 0.93 (0.13-6.7) 0.944 
 
68 2/343 0.6 0.39 (0.1-1.57) 0.185 
Zoledronate 93 0/88 0  - - 
 
82 1/288 0.3 0.21 (0.03-1.53) 0.125 
Denosumab 23 0/22 0  - - 
 
19 0/54 0  - - 
Raloxifene 4 0/4 0  - - 
 
3 0/20 0  - - 
HRT 1 0/1 0  - - 
 
1 0/10 0  - - 
Salcatonin 103 6/84 7.1 4.96 (2.16-11.38) <0.001 
 
66 8/184 4.3 2.73 (1.35-5.51) 0.005 
Strontium ranelate 87 3/78 3.8 2.67 (0.84-8.45) 0.096 
 
66 10/278 3.6 2.33 (1.24-4.37) 0.009 
Teriparatide 21 0/19 0  - - 
 
19 0/44 0  - - 
Stratified by drug class 
     
     
Bisphosphonate 2572 22/2450 0.9 0.62 (0.39-1) 0.052 
 
1993 106/9621 1.1 0.71 (0.57-0.89) 0.003 
Non-bisphosphonate 239 9/207 4.3 3.01 (1.51-6) 0.002 
 
174 18/589 3.1 1.93 (1.2-3.12) 0.007 
Abbreviations: py person-year; HRT hormone replacement therapy; PS propensity score 
  





N No. of death/py 
Mortality 
rate, per 100 
py 
Relative risk 
 (95% CI) 




rate, per 100 
py 
Relative risk 
 (95% CI) 
P 
Untreated 1738 73/1699 4.3  - - 
 
1068 208/4597 4.5  - - 
Treated 931 25/919 2.7 0.63 (0.4-1) 0.048 
 
600 113/2905 3.9 0.87 (0.69-1.1) 0.247 
Stratified by individual drug 
     
     
Alendronate 629 14/607 2.3 0.54 (0.3-0.95) 0.033 
 
443 76/1887 4 0.88 (0.67-1.14) 0.326 
Ibandronate 144 4/133 3 0.7 (0.26-1.93) 0.494 
 
86 17/378 4.5 1.04 (0.63-1.7) 0.887 
Risedronate 19 0/18  - -  - 
 
10 2/58 3.4 0.92 (0.23-3.7) 0.905 
Zoledronate 39 0/38  - -  - 
 
32 1/105 1 0.19 (0.03-1.35) 0.096 
Denosumab 7 1/6 16.7 3.81 (0.53-27.4) 0.184 
 
7 2/18 11.1 2.18 (0.54-8.79) 0.273 
Raloxifene 1 0/1  - -  - 
 
1 0/1 0  - - 
HRT 0 0/  - -  - 
 
0 0/  - -  - 
Salcatonin 45 3/35 8.6 2 (0.63-6.33) 0.241 
 
29 5/90 5.6 1.33 (0.55-3.23) 0.529 
Strontium ranelate 45 2/40 5 1.17 (0.29-4.75) 0.83 
 
28 5/101 5 1.1 (0.45-2.67) 0.837 
Teriparatide 6 0/4 0  - - 
 
6 0/7 0  - - 
Stratified by drug class 
     
     
Bisphosphonate 831 18/796 2.3 0.53 (0.31-0.88) 0.015 
 
571 96/2427 4 0.87 (0.68-1.11) 0.252 
Non-bisphosphonate 104 6/87 6.9 1.63 (0.71-3.74) 0.253 
 
71 12/217 5.5 1.24 (0.69-2.22) 0.466 
 
  
Figure 1 Case selection chart 
 
  
Figure 2 Propensity score distribution before and after matching 
 
 
